{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:37:59Z","timestamp":1777250279153,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02646-z","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:02:21Z","timestamp":1777248141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study"],"prefix":"10.1038","volume":"11","author":[{"given":"Lin","family":"Gui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yufu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meifang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesheng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangshuang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"2646_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","volume":"5","author":"A Carbone","year":"2019","unstructured":"Carbone, A. et al. Follicular lymphoma. Nat. Rev. Dis. Prim. 5, 83 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2646_CR2","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","volume":"97","author":"E Jacobsen","year":"2022","unstructured":"Jacobsen, E. Follicular lymphoma: 2023 update on diagnosis and management. Am. J. Hematol. 97, 1638\u20131651 (2022).","journal-title":"Am. J. Hematol."},{"key":"2646_CR3","first-page":"443","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras, L. R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 66, 443\u2013459 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"2646_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1746-1596-6-77","volume":"6","author":"Q-P Yang","year":"2011","unstructured":"Yang, Q.-P. et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn. Pathol. 6, 77 (2011).","journal-title":"Diagn. Pathol."},{"key":"2646_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/hon.2202","volume":"34","author":"X-M Wang","year":"2016","unstructured":"Wang, X.-M. et al. Clinical analysis of 1629 newly diagnosed malignant lymphomas in current residents of Sichuan province, China. Hematol. Oncol. 34, 193\u2013199 (2016).","journal-title":"Hematol. Oncol."},{"key":"2646_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377, 42\u201351 (2011).","journal-title":"Lancet"},{"key":"2646_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ajco.13463","volume":"17","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study. Asia Pac. J. Clin. Oncol. 17, 289\u2013299 (2021).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"2646_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32\u201342 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"2646_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/ng1531","volume":"37","author":"MF Fraga","year":"2005","unstructured":"Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet 37, 391\u2013400 (2005).","journal-title":"Nat. Genet"},{"key":"2646_CR10","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1182\/blood-2012-12-451799","volume":"121","author":"Y Jiang","year":"2013","unstructured":"Jiang, Y., Hatzi, K. & Shaknovich, R. Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood 121, 4271\u20134279 (2013).","journal-title":"Blood"},{"key":"2646_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","volume":"13","author":"KJ Falkenberg","year":"2014","unstructured":"Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673\u2013691 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2646_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic, M. et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109, 31\u201339 (2007).","journal-title":"Blood"},{"key":"2646_CR13","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen, E. A. et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 3109\u20133115 (2007).","journal-title":"J. Clin. Oncol."},{"key":"2646_CR14","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz, R. L. et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27, 5410\u20135417 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2646_CR15","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","volume":"28","author":"SJ Whittaker","year":"2010","unstructured":"Whittaker, S. J. et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28, 4485\u20134491 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2646_CR16","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, O. A. et al. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J. Clin. Oncol. 33, 2492\u20132499 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2646_CR17","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi, Y. et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann. Oncol. 26, 1766\u20131771 (2015).","journal-title":"Ann. Oncol."},{"key":"2646_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J. Hematol. Oncol. 10, 69 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"2646_CR19","doi-asserted-by":"publisher","first-page":"LBA7003","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7003","volume":"42","author":"W Zhao","year":"2024","unstructured":"Zhao, W. et al. Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: an interim analysis from the phase III DEB study. JCO 42, LBA7003\u2013LBA7003 (2024).","journal-title":"JCO"},{"key":"2646_CR20","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","volume":"29","author":"M Kirschbaum","year":"2011","unstructured":"Kirschbaum, M. et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 1198\u20131203 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2646_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3324\/haematol.2014.117473","volume":"100","author":"R Chen","year":"2015","unstructured":"Chen, R. et al. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed\/refractory indolent non-Hodgkin lymphoma. Haematologica 100, 357\u2013362 (2015).","journal-title":"Haematologica"},{"key":"2646_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/bjh.16008","volume":"186","author":"SE Spurgeon","year":"2019","unstructured":"Spurgeon, S. E. et al. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. Br. J. Haematol. 186, 845\u2013854 (2019).","journal-title":"Br. J. Haematol."},{"key":"2646_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14370-y","volume":"25","author":"L Gui","year":"2025","unstructured":"Gui, L. et al. Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed\/refractory B cell non-Hodgkin lymphoma: a Phase 1 study. BMC Cancer 25, 967 (2025).","journal-title":"BMC Cancer"},{"key":"2646_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.semcancer.2020.11.005","volume":"83","author":"B Biersack","year":"2022","unstructured":"Biersack, B., Polat, S. & H\u00f6pfner, M. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin. Cancer Biol. 83, 472\u2013486 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"2646_CR25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10637-015-0206-x","volume":"33","author":"F Morschhauser","year":"2015","unstructured":"Morschhauser, F. et al. Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Investig. N. Drugs 33, 423\u2013431 (2015).","journal-title":"Investig. N. Drugs"},{"key":"2646_CR26","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","volume":"22","author":"AM Evens","year":"2016","unstructured":"Evens, A. M. et al. A Phase I\/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed\/Refractory Lymphoma. Clin. Cancer Res. 22, 1059\u20131066 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2646_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3324\/haematol.2016.154377","volume":"102","author":"V Ribrag","year":"2017","unstructured":"Ribrag, V. et al. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica 102, 903\u2013909 (2017).","journal-title":"Haematologica"},{"key":"2646_CR28","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1158\/1078-0432.CCR-08-2365","volume":"15","author":"S Bhalla","year":"2009","unstructured":"Bhalla, S. et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin. Cancer Res. 15, 3354\u20133365 (2009).","journal-title":"Clin. Cancer Res."},{"key":"2646_CR29","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines for B-Cell Lymphomas (Version 2.2025). National Comprehensive Cancer Network. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (2025)."},{"key":"2646_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde, L. E. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 23, 1055\u20131065 (2022).","journal-title":"Lancet Oncol."},{"key":"2646_CR31","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","volume":"11","author":"KM Linton","year":"2024","unstructured":"Linton, K. M. et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 11, e593\u2013e605 (2024).","journal-title":"Lancet Haematol."},{"key":"2646_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91\u2013103 (2022).","journal-title":"Lancet Oncol."},{"key":"2646_CR33","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu, S. S. et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143, 496\u2013506 (2024).","journal-title":"Blood"},{"key":"2646_CR34","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28, 325\u2013332 (2022).","journal-title":"Nat. Med."},{"key":"2646_CR35","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","volume":"30","author":"F Morschhauser","year":"2024","unstructured":"Morschhauser, F. et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat. Med. 30, 2199\u20132207 (2024).","journal-title":"Nat. Med."},{"key":"2646_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser, F. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 21, 1433\u20131442 (2020).","journal-title":"Lancet Oncol."},{"key":"2646_CR37","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","volume":"41","author":"PL Zinzani","year":"2023","unstructured":"Zinzani, P. L. et al. ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J. Clin. Oncol. 41, 5107\u20135117 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2646_CR38","doi-asserted-by":"publisher","first-page":"S827","DOI":"10.1016\/j.annonc.2022.07.744","volume":"33","author":"YK Shi","year":"2022","unstructured":"Shi, Y. K. et al. 618O A phase I study of TRS005: an anti-CD20-MMAE antibody-drug conjugate, in relapsed or refractory b cell non-Hodgkin lymphoma. Ann. Oncol. 33, S827 (2022).","journal-title":"Ann. Oncol."},{"key":"2646_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-024-01646-2","volume":"17","author":"J Yang","year":"2024","unstructured":"Yang, J. et al. Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRP\u03b1, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1\/2 study. J. Hematol. Oncol. 17, 123 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2646_CR40","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1007\/s13238-020-00694-x","volume":"11","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell 11, 472\u2013482 (2020).","journal-title":"Protein Cell"},{"key":"2646_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841716","volume":"13","author":"C Ripamonti","year":"2022","unstructured":"Ripamonti, C. et al. HDAC Inhibition as Potential Therapeutic Strategy to Restore the Deregulated Immune Response in Severe COVID-19. Front. Immunol. 13, 841716 (2022).","journal-title":"Front. Immunol."},{"key":"2646_CR42","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2646_CR43","unstructured":"US Department of Health and Human Services, Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.National Institutes of Health. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf (2017)."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02646-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02646-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02646-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:02:22Z","timestamp":1777248142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02646-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2646"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02646-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Wentao Wu was an employee of Xynomic Pharmaceuticals (Nanjing) Co., Ltd. Nanjing, China. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}